The Journal of infectious diseases · 2026
Maternal-Fetal Letermovir Exposure In Vivo and Physiologically Based Pharmacokinetic Modeling: A Rationale for Congenital Cytomegalovirus Therapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Faure Bardon Valentine, Bouazza Naim, Peytavin Gilles, Patrick Le Minh, Benaboud Sihem, Foissac Frantz, Lui Gabrielle, Froelicher-Bournaud Léo, Urien Saïk, Bessieres Bettina, Guilleminot Tiffany, Bussieres Laurence, Treluyer Jean-Marc, Leruez-Ville Marianne, Ville Yves
Аннотация
BACKGROUND: Cytomegalovirus (CMV) affects 0.5%-2.0% of all live births and is the main nongenetic cause of congenital sensorineural hearing loss and neurological damage, yet no validated prenatal treatment exists for infected fetuses. Letermovir, a CMV-specific antiviral, is approved for prophylaxis in transplant recipients. This study aimed to quantify maternal-fetal exposure to letermovir following maternal administration, focusing on CMV-target fetal organs, particularly the brain.
METHODS: Seven pregnant women undergoing second-trimester termination of pregnancy for fetal anomalies received oral letermovir (240 or 480 mg once daily) for 3 days. On the day of termination, samples from maternal and fetal blood, placenta, and fetal organs were collected and analyzed. Plasma and tissue drug concentrations were compared to the letermovir half-maximal effective concentration to assess potential antiviral efficacy.
RESULTS: Letermovir achieved therapeutic levels in all compartments. Complementary physiologically based pharmacokinetic modeling confirmed adequate fetal exposure across pregnancy stages. No maternal adverse events were observed.
CONCLUSIONS: These unique in vivo data provide the first pharmacological rationale supporting letermovir use during pregnancy for congenital CMV therapy. Clinical Trials Registration. NCT04732260.
METHODS: Seven pregnant women undergoing second-trimester termination of pregnancy for fetal anomalies received oral letermovir (240 or 480 mg once daily) for 3 days. On the day of termination, samples from maternal and fetal blood, placenta, and fetal organs were collected and analyzed. Plasma and tissue drug concentrations were compared to the letermovir half-maximal effective concentration to assess potential antiviral efficacy.
RESULTS: Letermovir achieved therapeutic levels in all compartments. Complementary physiologically based pharmacokinetic modeling confirmed adequate fetal exposure across pregnancy stages. No maternal adverse events were observed.
CONCLUSIONS: These unique in vivo data provide the first pharmacological rationale supporting letermovir use during pregnancy for congenital CMV therapy. Clinical Trials Registration. NCT04732260.